KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Debt (2016 - 2025)

Historic Total Debt for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $1.6 billion.

  • BeOne Medicines' Total Debt rose 5657.05% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 5657.05%. This contributed to the annual value of $1.0 billion for FY2024, which is 1490.2% up from last year.
  • Latest data reveals that BeOne Medicines reported Total Debt of $1.6 billion as of Q3 2025, which was up 5657.05% from $954.5 million recorded in Q2 2025.
  • BeOne Medicines' Total Debt's 5-year high stood at $1.6 billion during Q3 2025, with a 5-year trough of $488.1 million in Q1 2023.
  • Over the past 5 years, BeOne Medicines' median Total Debt value was $643.3 million (recorded in 2021), while the average stood at $790.6 million.
  • Its Total Debt has fluctuated over the past 5 years, first skyrocketed by 28463.44% in 2021, then tumbled by 1985.02% in 2023.
  • BeOne Medicines' Total Debt (Quarter) stood at $629.7 million in 2021, then dropped by 19.48% to $507.0 million in 2022, then surged by 74.74% to $886.0 million in 2023, then grew by 14.9% to $1.0 billion in 2024, then soared by 61.69% to $1.6 billion in 2025.
  • Its Total Debt stands at $1.6 billion for Q3 2025, versus $954.5 million for Q2 2025 and $923.6 million for Q1 2025.